Safety & Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin Deficiency

Condition(s) targeted: Alpha-1 Antitrypsin Deficiency

Intervention: rAAV1-CB-hAAT (Drug)

Phase: Phase 2

Status: Recruiting

Sponsored by: Applied Genetic Technologies Corp

Official(s) and/or principal investigator(s):
Terence R. Flotte, MD, Principal Investigator, Affiliation: University of Massachusetts Medical School, Worcester, MA
Bruce C. Trapnell, MD, Principal Investigator, Affiliation: Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Robert A. Sandhaus, MD, PhD, Principal Investigator, Affiliation: National Jewish Health, Denver, CO
Noel G. McElvaney, MB, BCh, BAO, Principal Investigator, Affiliation: Beaumont Hospital, Dublin, Ireland

This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector expressing alpha-1 antitrypsin in patients with alpha-1 antitrypsin deficiency. Three groups of three subjects each will receive the study drug by intramuscular injection, with progressively larger doses in the second and third groups.

Official title: A Multiple-Site, Phase 2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing Alpha-1 Antitrypsin (rAAV1-CB-hAAT) in Patients With Alpha-1 Antitrypsin Deficiency

Study design: Allocation: Non-Randomized, Control: Uncontrolled, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Frequency of Grade 3 or 4 adverse events

Secondary outcome:

Changes in serum M-specific alpha-1 antitrypsin concentration

Changes in serum total alpha-1 antitrypsin concentrations

Detailed description: The study is a non-randomized, open-label, multi-center, sequential, three-arm, Phase 2 clinical trial evaluating the safety and efficacy of administration of a rAAV1-CB-hAAT vector administered by IM injection. Each participant will receive rAAV1-CB-hAAT on a single occasion. Three groups of three subjects each will receive rAAV1-CB-hAAT at dosage levels of 6 x 10e11 vg/kg, 1. 9 x 10e12 vg/kg or 6 x 10e12 vg/kg by IM injection. Subjects in group 1 will receive a total of 10 IM injections distributed across a single muscle site, subjects in group 2 will receive a total of 32 IM injections distributed across three muscle sites, and subjects in group 3 will receive 100 IM injections distributed across 10 muscle sites. Each injection will be given in a volume of 1. 35 mL, at the appropriate vector concentration to achieve the desired total vector dose, and the injection density at each administration site (nine IM injections per 4 cm2 skin surface area) will be the same as the injection density that was well tolerated in a previous Phase 1 clinical trial with rAAV1-CB-hAAT. Safety will be monitored by evaluation of adverse events, hematology and clinical chemistry parameters, histological examination of muscle biopsies, and measurement of serum antibodies to AAT. Efficacy will be measured by evaluation of serum concentrations of M-specific AAT and total AAT and serum AAT phenotype determined on isoelectric focusing gels. Additional information to be collected will include presence of the vector in blood or semen, changes in serum anti-AAV antibody titers, and changes in T cell responses to AAV and AAT.

Minimum age: 18 Years. Maximum age: 75 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

1. Have a diagnosis of AAT-deficiency, as defined by a serum AAT level of less than 11 µM and a phenotype or genotype either homozygous for PI*Z or compound heterozygous consisting of PI*Z and another allele known to be associated with disease,

2. Be at least 18 and not more than 75 years of age,

3. Have a FEV1 >25% of predicted value (post bronchodilator),

4. Weigh ≤ 90 kg,

5. Not receiving AAT augmentation therapy currently or with the past 3 months, and not planning to begin such therapy for at least 12 months after administration of rAAV1-CB-hAAT,

6. Be willing to discontinue aspirin, aspirin-containing products, and other drugs that may alter platelet function, 7 days prior to dosing, resuming no earlier than 24 hours after the dose has been administered,

7. Have acceptable laboratory parameters

8. For females of childbearing potential:

- A negative pregnancy test (urine or serum) at screening and at baseline (within

2 days before administration of study agent),

- Agreement to consistently use barrier contraception (condoms, diaphragm or

cervical cap with spermicide) or another form of contraception (e. g. intrauterine device or hormonal contraception) from the screening visit until 12 months after administration of rAAV1-CB-hAAT, for sexual activity that could lead to pregnancy.

9. For males of reproductive potential, agreement to consistently use barrier contraception (condoms with spermicide) for 12 months after administration of rAAV1-CB-hAAT, for sexual activity that could lead to pregnancy,

10. Provide signed informed consent before screening.

Exclusion Criteria:

1. Prior receipt of any AAV gene therapy product,

2. Use of anticoagulants or anti-platelet agents within 7 days prior to study agent administration,

3. History of immune response to human AAT augmentation therapy as indicated by clinical history of an adverse immune response to infusion and/or decreased therapeutic effect in combination with documentation of serum anti-AAT antibodies,

4. Use of acute oral or intravenous antibiotic therapy for a respiratory infection within 28 days prior to study agent administration (long-term maintenance or chronic suppressive oral antibiotics, and antibiotics for a non-respiratory indication, are allowed),

5. Use of oral or systemic corticosteroids within 28 days prior to study agent administration,

6. Use of any investigational agent, or any immunosuppressive drug(s), within 3 months prior to enrollment,

7. For females of childbearing potential, a positive pregnancy test at screening or baseline (within 2 days before rAAV1-CB-hAAT administration),

8. Females who are breast feeding,

9. Have a significant abnormal EKG finding at screening and/or cardiac disease (e. g. recent myocardial infarction or CHF) within past 6 months,

10. Have had pulmonary edema or a pulmonary embolism within the past 6 months,

11. Have a history of immunodeficiency or other medical condition which leads the investigator to believe that the participant cannot comply with the protocol requirements or that may place the participant at an unacceptable risk for participation.

Beaumont Hospital, Dublin 2, Ireland; Not yet recruiting
Noel G. McElvaney, MB, BCh, BAO, Phone: +353 (1) 8093764, Email: gmcelvaney@rcsi.ie
Grace Mullins, RN, Phone: +353 (0) 1 8093864, Email: gracemullins@rcsi.ie
Noel G. McElvaney, MB, BCh, BAO, Principal Investigator
Muirne Spooner, Sub-Investigator

National Jewish Health, Denver, Colorado 80206, United States; Not yet recruiting
Robert A. Sandhaus, MD, PhD, Phone: 303-270-2051, Email: SandhausR@NJHealth.org
Robert A. Sandhaus, MD, PhD, Principal Investigator

University of Massachusetts Medical Center, Worcester, Massachusetts 01655, United States; Recruiting
Margaret Humprhies, RN, Phone: 508-856-5711, Email: Margaret.Humphries@umassmed.edu
Terence R. Flotte, MD, Phone: (508) 856-8000, Email: Terry.Flotte@umassmed.edu
Terence R. Flotte, MD, Principal Investigator

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229, United States; Recruiting
Brenna Carey, PhD, Phone: 513-636-8916, Email: Brenna.Carey@cchmc.org
Leslie Korbee, BS SI(ASCP), Phone: (513) 636-6272, Email: leslie.korbee@cchmc.org
Bruce C. Trapnell, MD, Principal Investigator

Applied Genetic Technologies Corporation

Related publications:

Brantly ML, Chulay JD, Wang L, Mueller C, Humphries M, Spencer LT, Rouhani F, Conlon TJ, Calcedo R, Betts MR, Spencer C, Byrne BJ, Wilson JM, Flotte TR. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16363-8. Epub 2009 Aug 12. Erratum in: Proc Natl Acad Sci U S A. 2009 Oct 13;106(41):17606.

Starting date: March 2010
Last updated: September 16, 2010